Every 10-Q that LivaNova PLC (LIVN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LIVN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LIVN filings page.
LivaNova PLC reported solid growth for the three and six months ended June 30, 2026. Net revenue was about $390.6 million for the quarter and $752.8 million year‑to‑date, up 10.8% and 12.5% from 2025, with contributions from both Cardiopulmonary and Neuromodulation across all regions.
Net income was about $108.6 million for the quarter and $130.9 million year‑to‑date, compared with $27.2 million and a $300.2 million loss a year earlier. Results reflect lower cost of sales as a percentage of revenue and a $95.4 million discrete Italian tax benefit related to the SNIA environmental liability.
Cash and cash equivalents were $516.6 million, and long‑term debt decreased to $289.9 million after full repayment of Term Facilities, leaving the 2.50% 2029 Notes as the primary borrowing. The balance sheet also carries sizeable obligations, including a $385.0 million SNIA environmental liability, $41.5 million Saluggia site provision, and $23.1 million 3T Heater‑Cooler litigation reserve.
LivaNova PLC reported stronger results for the quarter ended March 31, 2026, with net revenue of $362.3 million, up 14.3% from the prior-year period. The company generated net income of $22.3 million, compared with a net loss of $327.3 million a year earlier, when it recorded a large SNIA environmental liability charge.
Cardiopulmonary revenue rose 18.3% to $208.7 million, helped by Essenz Perfusion System sales and consumables demand, while Neuromodulation revenue grew 9.3% to $151.8 million on higher implants and pricing. Operating income declined modestly to $41.5 million as research and development spending increased, including expenses tied to ImThera contingent consideration and sleep apnea device development.
The company ended the quarter with cash and cash equivalents of $539.7 million and total debt of $287.8 million after early repaying $95.9 million under its term facilities. LivaNova recorded a current SNIA environmental liability of $389.5 million and a Saluggia site environmental provision of $41.0 million, and noted it believes it has sufficient resources to satisfy the SNIA obligation.
LivaNova PLC reported stronger Q3 2025 results. Net revenue rose to $357.8 million from $318.1 million, with operating income of $54.0 million and net income of $26.8 million ($0.49 diluted). For the first nine months, the company posted a net loss of $273.4 million, primarily driven by the $363.8 million SNIA environmental liability expense booked earlier in the year.
Cash and cash equivalents were $646.1 million, aided by operating cash flow of $171.9 million year-to-date. LivaNova repaid $200 million on its Term Facilities in May, reducing long-term debt to $349.0 million. The company recorded a current liability of $394.6 million (€336.3 million) related to the SNIA matter, reflecting its best estimate including costs, fees, interest, and taxes.
On the cybersecurity incident disclosed in 2023, cumulative direct costs totaled $13.1 million through September 30, 2025, and insurance reimbursements received totaled $9.6 million. Ordinary shares outstanding were 54,605,527 as of October 29, 2025.
LivaNova PLC (LIVN) Q2-25 10-Q highlights:
- Net revenue rose 10.6% YoY to $352.5 m; six-month revenue up 9.1% to $669.4 m.
- Gross margin held steady at 67.8%; operating income jumped 34.9% to $54.2 m on disciplined SG&A (+10.1%) and R&D spend (-7.9%).
- GAAP EPS improved to $0.50 versus $0.30; diluted share count 54.7 m.
- Six-month results swung to a $300.2 m loss after booking a $362.1 m SNIA environmental charge.
- Cash climbed to $593.6 m (-$130 m q-o-q after releasing $294.7 m restricted cash); total debt reduced 31% to $430.6 m following a $200 m early term-loan repayment.
- SNIA litigation reserve now $392.3 m; €270 m surety bond in place pending appeal. Cyber-incident costs reached $13 m, with $9.6 m insurance recovery to date.
- Liquidity: $225 m revolver undrawn; operating cash flow +63% YoY to $86.9 m H1-25.
- No covenant breaches; capped-call and embedded derivatives re-measured, neutral P&L effect.
Management reaffirmed focus on core Cardiopulmonary & Neuromodulation segments and continues restructuring begun 2024. Litigation and environmental exposures remain the key overhang despite solid operating momentum and deleveraging.